JP6228674B2 - クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 - Google Patents
クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 Download PDFInfo
- Publication number
- JP6228674B2 JP6228674B2 JP2016530173A JP2016530173A JP6228674B2 JP 6228674 B2 JP6228674 B2 JP 6228674B2 JP 2016530173 A JP2016530173 A JP 2016530173A JP 2016530173 A JP2016530173 A JP 2016530173A JP 6228674 B2 JP6228674 B2 JP 6228674B2
- Authority
- JP
- Japan
- Prior art keywords
- probe
- target nucleic
- nucleic acid
- detection
- clamping
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims description 346
- 238000001514 detection method Methods 0.000 title claims description 151
- 150000007523 nucleic acids Chemical class 0.000 title claims description 135
- 102000039446 nucleic acids Human genes 0.000 title claims description 132
- 108020004707 nucleic acids Proteins 0.000 title claims description 132
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 123
- 108090000623 proteins and genes Proteins 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 75
- 230000003321 amplification Effects 0.000 claims description 70
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 70
- 238000002844 melting Methods 0.000 claims description 68
- 230000008018 melting Effects 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 62
- 230000035772 mutation Effects 0.000 claims description 50
- 238000003752 polymerase chain reaction Methods 0.000 claims description 27
- 238000003753 real-time PCR Methods 0.000 claims description 25
- 238000004458 analytical method Methods 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 229930182847 D-glutamic acid Natural products 0.000 claims description 8
- -1 Eclipse Chemical compound 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 229960002989 glutamic acid Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 230000004544 DNA amplification Effects 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical class [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 4
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012099 Alexa Fluor family Substances 0.000 claims description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 claims description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 26
- 206010069754 Acquired gene mutation Diseases 0.000 description 22
- 238000011880 melting curve analysis Methods 0.000 description 22
- 230000037439 somatic mutation Effects 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 239000002585 base Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000000833 heterodimer Substances 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 11
- 101710113436 GTPase KRas Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000013211 curve analysis Methods 0.000 description 10
- 102200006541 rs121913530 Human genes 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 102200006537 rs121913529 Human genes 0.000 description 7
- 102200006538 rs121913530 Human genes 0.000 description 7
- 102200006540 rs121913530 Human genes 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 102200006531 rs121913529 Human genes 0.000 description 6
- 102200006539 rs121913529 Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010069755 K-ras gene mutation Diseases 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229930195714 L-glutamate Natural products 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 102200006532 rs112445441 Human genes 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- MKLSLVKLQOIPCY-QRLADXQJSA-N (2r)-2-aminopropanoic acid Chemical compound C[C@@H](N)C(O)=O.C[C@@H](N)C(O)=O MKLSLVKLQOIPCY-QRLADXQJSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 2
- 229930195715 D-glutamine Natural products 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 206010071975 EGFR gene mutation Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- FRIHGXGYWUWBED-BXXIVHCWSA-N NCCCC[C@@H](N)C(O)=O.NCCCC[C@@H](N)C(O)=O Chemical compound NCCCC[C@@H](N)C(O)=O.NCCCC[C@@H](N)C(O)=O FRIHGXGYWUWBED-BXXIVHCWSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- MKLSLVKLQOIPCY-QNDGGIRCSA-N (2r)-2-aminopropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@@H](N)C(O)=O.C[C@H](N)C(O)=O MKLSLVKLQOIPCY-QNDGGIRCSA-N 0.000 description 1
- FRIHGXGYWUWBED-ZLELNMGESA-N (2s)-2,6-bis(azanyl)hexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O FRIHGXGYWUWBED-ZLELNMGESA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- NFSGQYGMPDCEFD-UHFFFAOYSA-N 2-amino-n-(2-aminoethyl)acetamide Chemical compound NCCNC(=O)CN NFSGQYGMPDCEFD-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000593245 Bionia Species 0.000 description 1
- 241001654587 Bonia Species 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000006809 Pancreatic Fistula Diseases 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- UJKDYMOBUGTJLZ-RUCXOUQFSA-N ksc605q1h Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O UJKDYMOBUGTJLZ-RUCXOUQFSA-N 0.000 description 1
- MKLSLVKLQOIPCY-BXRBKJIMSA-N l-alanin-l-alanin Chemical compound C[C@H](N)C(O)=O.C[C@H](N)C(O)=O MKLSLVKLQOIPCY-BXRBKJIMSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
[77]以下、実施例を通じて本発明をさらに詳しく説明する。これら実施例は単に本発明を例示するためのものであって、本発明の範囲がこれら実施例により制限されるものと解釈されないことは、当業界において通常の知識を有する者にとって自明である。
[81]1−1:PNAプローブの作製
[82]本発明の立体構造の変化及び電荷付与を通じた構造的変化を与えた検出プローブ(detection probe)及びクランピングプローブ(clamping probe)で構成されたPNA混合体を用いた突然変異の検出方法の具現及び作動可能性を確認するために、表1のように、PNAプローブ骨格のガンマ位置に負電荷を有するL−グルタミン酸(L−glutamic acid)またはD−グルタミン酸(D−glutamic acid)、電荷を有さないL−アラニン(L−alanine)またはD−アラニン(D−alanine)、正電荷を有するL−リシン(L−lysine)またはD−リシン(D−lysine)を結合させたPNAプローブを合成した。
[93]上記表1で作製したPNAプローブの特性を分析するために、PNAプローブと結合をなすターゲットDNAオリゴマー(表3)は、(株)バイオニア(韓国)で合成依頼して用いた。
[100]実施例1−1で製造したPNAプローブのセルフダイマー、ヘテロダイマーの形成及び特異度に関して分析するために、上記の表1のPNAプローブ0.5μM、表3のDNAオリゴマー0.5μMとPCR増幅溶液(Enzynomics、韓国)を入れて混合した後、リアルタイム遺伝子増幅機(Real−time PCR machine、CFX96TM Real−time PCR System、バイオ・ラッド、米国)を用いて95℃で5分間変性ステップを経た後、30℃まで下げた後に5分間混成化させた後、30℃から95℃まで0.5℃ずつ上昇させつつ、蛍光を測定する融解曲線分析を行った。
[110]体細胞突然変異の同時多重検出のための標的核酸は、代表的な体細胞突然変異遺伝子であるK−ras(V−Ki−ras2 Kirsten rat sarcoma viral oncogene homolog)遺伝子を用いて実験を行った。韓国細胞株銀行からK−rasコドン12及び13の野生型細胞株1種(HeLa)及び突然変異細胞株5種(SW−1116、A549、SW48、MIA PaCa2、LoVo)の分譲を受けた(表5)。
[124]4−1:体細胞突然変異の同時多重検出のためのPNAプローブ及びPCRプライマー混合液の作製
[125]体細胞突然変異の同時多重検出のために、表1の配列番号15PNAプローブ13.5μM、配列番号16〜18のPNAプローブ18μM、配列番号19のPNAプローブ9μM、配列番号20のPNAプローブ18μM、配列番号22のPNAプローブ4.5μMの濃度になるように稀釈させたPNAプローブを同一の量で混合してPNAプローブ混合液を製造した。次に、配列番号26の正方向プライマー1.5μM、配列番号27の逆方向プライマー20μM濃度になるように稀釈させた後、各プライマーを同一の量で混合した。
[129]実施例4−1で製造したPNAプローブPCRプライマー混合液10μl、PCR増幅溶液(Enzynomics、韓国)10μlを混合した後、実施例3で作製された(表5、表6)各標的核酸を5μlずつ添加後、リアルタイムPCR反応を行った(Real−time PCR machine、CFX96TM Real−time PCR System、バイオ・ラッド、米国)。PCRサイクルは、95℃で15分間反応後、95℃10秒、76℃7秒、53℃20秒、72℃20秒の反応過程を45cycle繰り返し、蛍光検出は53℃で測定し、この後、蛍光測定なしに95℃10秒、76℃7秒、53℃20秒、72℃20秒の反応過程を10サイクル繰り返してPCR反応を完了した。PCRサイクルの完了後、95℃で5分間変性ステップを経た後、48℃まで下げた後に5分間混成化させた後、48℃から95℃まで0.5℃ずつ上昇させて蛍光を測定する融解曲線分析を行った。
[138]本発明の検出プローブがPNA以外の他の核酸類似体である場合も、体細胞突然変異の検出が可能であるか否かを確認するためにMGB−taqmanを検出プローブで用いてEGFR遺伝子突然変異を検出した。
[140]韓国細胞株銀行から野生型細胞株であるA549を、ATCCからEGFR遺伝子突然変異細胞株であるH1975の分譲を受けて標的核酸を作製した(表9)。
[146]突然変異検出のためのプライマー(配列番号28、29)は、(株)バイオニア(韓国)で合成依頼して用い(表10)、MGB−taqman突然変異検出用プローブ(配列番号30)は、ABI(Applied Biosystems、USA)に合成依頼して用いた(表11)。PNAクランピングプローブは実施例1に明示された方法と同一の方法で合成された。
[158]6−1:PNAプローブの作製
[159]PNAプローブ及びPNAの立体構造及び電荷付与を通じて構造的変化を与えた検出プローブ(detection probe)及びクランピングプローブ(clamping probe)で構成されたPNA混合体を用いて突然変異検出のために表12のようにPNAプローブを合成した。
[169]表12で製造したPNAプローブ配列とDNAターゲットとの間の結合特異性は、検出PNAプローブ10μMと野生型クランピングPNAプローブ4μM、ターゲットDNA及びPCR増幅溶液(Enzynomics、韓国)を混合してPCR反応後、融解曲線分析を通じてPNAプローブの特異性を分析した。PCR反応は、リアルタイム遺伝子増幅機(Real−time PCR machine、CFX96TM Real−time PCR System、バイオ・ラッド、米国)を用いた。その結果、PNAプローブ配列と混合したターゲットの配列一致率により融解曲線が明確に区分されるプローブを確認した。配列番号33、34 37、38検出プローブでターゲットDNAの塩基配列別選別能に優れたグラフを確認した(図13、14、15)。検出プローブと塩基配列が完全に一致するターゲットと不一致するターゲットとの間に発生するTm分析結果の例示は表14に示した。
[175]標的核酸の作製及び確保は、実施例3と同一の方法で行い、野生型遺伝子に各突然変異遺伝子を1%、0.1%、0.01%、0%含有されるようにサンプルを作製した(表15)。
[185]8−1:体細胞突然変異の同時多重検出及び検出敏感度の向上のためのPNAプローブ及びPCRプライマー混合液の作製
[186]体細胞突然変異の同時多重検出及び敏感度の向上のために、表12のプローブを配列番号35または36クランピングPNAプローブ4μM、配列番号32〜34、37〜38PNAプローブ10μMの濃度になるようにそれぞれ稀釈してPNAプローブ混合液を製造した。次に、配列番号39及び40の正方向プライマー3μM、配列番号41及び42の逆方向プライマー10μM濃度になるように稀釈後、各プライマーによる結果を確認した。
[189]8−1で製造したPNAプローブPCRプライマー混合液10μl、PCR増幅溶液(Enzynomics、韓国)10μlを混合した後、準備したターゲットDNA試料をそれぞれ5μlずつ添加してリアルタイムPCR反応を行った(Real−time PCR machine、CFX96TM Real−time PCR System、バイオ・ラッド、米国)。PCRサイクルは大きく、クランピング反応、検出反応及び融解反応の3つのステップに分けて進行し、95℃で15分間反応後、95℃30秒、70℃20秒、63℃30秒、72℃30秒の反応過程を蛍光測定なしに15cycle繰り返した後、95℃で10秒、53℃20秒、72℃20秒の反応過程を40cycle行い、蛍光は53℃で測定した。その後、95℃で15分間維持後、35℃まで下げた後に5分間混成化させた後、35℃から75℃まで0.5℃ずつ上昇させつつ蛍光を測定して融解曲線分析を行った。
Claims (24)
- 標的核酸をリアルタイムで検出するための一つ以上の検出プローブ(detection probe)及び野生型遺伝子または望まない遺伝子の増幅を抑制するクランピングプローブ(clamping probe)を含み、
増幅曲線及び融解曲線を同時分析し、0.01%突然変異までリアルタイム及び同時多重的に検出するためのプローブ混合体であって、
前記検出プローブまたはクランピングプローブは、構造的変形のためにアミノ酸またはアミノ酸の側鎖が結合されており、前記アミノ酸は、L−グルタミン酸、D−グルタミン酸、L−アラニン、D−アラニン、L−リシン及びD−リシンからなる群より選択されるものである、プローブ混合体。 - 前記検出プローブまたはクランピングプローブは核酸類似体であって、オリゴヌクレオチド(oligonucleotide)、PNA(peptide nucleic acids)及びLNA(Locked nucleic acid)からなる群よりそれぞれ選択されることを特徴とする請求項1に記載のプローブ混合体。
- 前記アミノ酸はプローブのN末端またはC末端位置に結合されることを特徴とする請求項1に記載のプローブ混合体。
- 前記アミノ酸の側鎖は、プローブ骨格のアルファ、ベータまたはガンマ位置に結合されることを特徴とする請求項1に記載のプローブ混合体。
- 前記検出プローブは、リポーター(reporter)及び消光子(quencher)が結合されたことを特徴とする請求項1に記載のプローブ混合体。
- 前記リポーター(reporter)は、フルオレセイン(fluorescein)、フルオレセインクロロトリアジニル(fluorescein chlorotriazinyl)、ロダミングリーン(rhodamine green)、ロダミンレッド(rhodamine red)、テトラメチルロダミン(tetramethylrhodamine)、FITC、オレゴングリーン(Oregon green)、アレクサフルオロ(Alexa Fluor)、FAM、JOE、ROX、HEX、テキサスレッド(Texas Red)、TET、TRITC、TAMRA、シアニン(Cyanine)系列染料及びチアジカルボシアニン(thiadicarbocyanine)染料で構成された群より選択された一つ以上の蛍光物質であることを特徴とする請求項5に記載のプローブ混合体。
- 前記消光子(quencher)は、ダブシル(Dabcyl)、TAMRA、Eclipse、DDQ、QSY、ブラックベリークエンチャ(Blackberry Quencher)、ブラックホールクエンチャ(Black Hole Quencher)、Qxl、アイオワブラック(Iowa black)FQ、アイオワブラックRQ及びIRDye QC−1群より選択された一つ以上であることを特徴とする請求項5に記載のプローブ混合体。
- 標的核酸をリアルタイムで検出するための一つ以上の検出プローブ(detection probe)及び野生型遺伝子または望まない遺伝子の増幅を抑制するクランピングプローブ(clamping probe)を含むプローブ混合体を用いた同時多重的標的核酸の検出方法であって、
増幅曲線及び融解曲線を同時分析し、0.01%突然変異までリアルタイム及び同時多重的に検出することができ、
前記検出プローブまたはクランピングプローブは、構造的変形のためにアミノ酸またはアミノ酸の側鎖が結合されており、前記アミノ酸は、L−グルタミン酸、D−グルタミン酸、L−アラニン、D−アラニン、L−リシン及びD−リシンからなる群より選択されるものである、同時多重的標的核酸の検出方法。 - 前記検出プローブまたはクランピングプローブは核酸類似体であって、オリゴヌクレオチド(oligonucleotide)、PNA(peptide nucleic acids)及びLNA(Locked nucleic acid)からなる群よりそれぞれ選択されることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記アミノ酸はプローブのN末端またはC末端位置に結合されることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記アミノ酸の側鎖は、プローブ骨格のアルファまたはベータ、ガンマ位置に結合されることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記検出プローブは、リポーター(reporter)及び消光子(quencher)が結合されたことを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記リポーター(reporter)は、フルオレセイン(fluorescein)、フルオレセインクロロトリアジニル(fluorescein chlorotriazinyl)、ロダミングリーン(rhodamine green)、ロダミンレッド(rhodamine red)、テトラメチルロダミン(tetramethylrhodamine)、FITC、オレゴングリーン(Oregon green)、アレクサフルオロ(Alexa Fluor)、FAM、JOE、ROX、HEX、テキサスレッド(Texas Red)、TET、TRITC、TAMRA、シアニン(Cyanine)系列染料及びチアジカルボシアニン(thiadicarbocyanine)染料で構成された群より選択された一つ以上の蛍光物質であることを特徴とする請求項12に記載の同時多重的標的核酸の検出方法。
- 前記消光子(quencher)は、ダブシル(Dabcyl)、TAMRA、Eclipse、DDQ、QSY、ブラックベリークエンチャ(Blackberry Quencher)、ブラックホールクエンチャ(Black Hole Quencher)、Qxl、アイオワブラック(Iowa black)FQ、アイオワブラックRQ及びIRDye QC−1群より選択された一つ以上であることを特徴とする請求項12に記載の同時多重的標的核酸の検出方法。
- 野生型遺伝子と相補的に結合して重合酵素の伸長反応を抑制するクランピングプローブを用いて標的核酸遺伝子を選択的に増幅させ、標的核酸を検出するための一つ以上の検出プローブを用いて同時多重的に標的核酸有無または濃度を検出することを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記検出プローブ及びクランピングプローブは、標的とする核酸鎖の同一ストランドに結合して野生型遺伝子の抑制及び標的核酸遺伝子の検出が同時になされることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記検出プローブ及びクランピングプローブは、標的とする核酸鎖の互いに異なるストランドに結合して野生型遺伝子の抑制及び標的核酸遺伝子の検出が同時になされることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- プローブ混合体を用いた標的核酸の検出は、リアルタイム増幅曲線及び融解曲線の同時分析が可能であることを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- (a)標的核酸が含まれている検体試料にクランピングプローブ及び検出プローブで構成されたプローブ混合体及びプライマーを混合して混成化させてリアルタイム増幅曲線を得るステップ;(b)前記増幅過程の後、温度を変化させつつ増幅産物と検出プローブとの間の融解曲線を得るステップ;及び(c)前記得られるリアルタイム増幅曲線及び融解曲線を別途に分析するか、あるいは順次的または同時に分析するステップ;を含むことを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 前記増幅は、リアルタイムPCR(polymerase chain reaction)を通じて行うことを特徴とする請求項19に記載の同時多重的標的核酸の検出方法。
- 前記(b)ステップの融解曲線を得るステップの前に、リアルタイム増幅曲線を得るステップとは別途に5乃至20のPCRサイクルを追加することを特徴とする請求項19に記載の同時多重的標的核酸の検出方法。
- (a)標的核酸が含まれている検体試料にクランピングプローブ及び検出プローブで構成されたプローブ混合体及びプライマーを混合して混成化させてリアルタイム増幅曲線を得るステップ;(b)前記得られるリアルタイム増幅曲線を分析するステップ;を含むことを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- (a)標的核酸が含まれている検体試料にクランピングプローブ及び検出プローブで構成されたプローブ混合体及びプライマーを混合して混成化させるステップ;(b)温度を変化させつつ、前記混成化された産物を融解させて融解曲線を得るステップ;及び(c)前記得られる融解曲線を分析するステップ;を含むことを特徴とする請求項8に記載の同時多重的標的核酸の検出方法。
- 請求項1〜7の何れか一項に記載のプローブ混合体を含む標的核酸同時多重検出用キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130136429 | 2013-11-11 | ||
KR10-2013-0136429 | 2013-11-11 | ||
KR1020140067582A KR101830700B1 (ko) | 2013-11-11 | 2014-06-03 | 클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법 |
KR10-2014-0067582 | 2014-06-03 | ||
PCT/KR2014/009611 WO2015068957A1 (en) | 2013-11-11 | 2014-10-14 | Method for the detection of multiple target nucleic acids using clamping probes and detection probes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017199346A Division JP2018033463A (ja) | 2013-11-11 | 2017-10-13 | クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017501683A JP2017501683A (ja) | 2017-01-19 |
JP6228674B2 true JP6228674B2 (ja) | 2017-11-08 |
Family
ID=53390725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016530173A Active JP6228674B2 (ja) | 2013-11-11 | 2014-10-14 | クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 |
JP2017199346A Pending JP2018033463A (ja) | 2013-11-11 | 2017-10-13 | クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017199346A Pending JP2018033463A (ja) | 2013-11-11 | 2017-10-13 | クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10648019B2 (ja) |
EP (1) | EP2912176B1 (ja) |
JP (2) | JP6228674B2 (ja) |
KR (1) | KR101830700B1 (ja) |
CN (1) | CN105765068A (ja) |
WO (1) | WO2015068957A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190001742A (ko) * | 2017-06-28 | 2019-01-07 | 주식회사 파나진 | 양자점을 분산광원으로 하는 표적 핵산 검출 방법 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10400277B2 (en) * | 2014-06-10 | 2019-09-03 | Diacarta Ltd | DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling |
EP3173488B1 (en) * | 2014-07-25 | 2020-09-09 | Panagene Inc. | Use of multiple target nucleic acid detection method using clamping probe and detection probe |
US10697004B2 (en) | 2014-11-06 | 2020-06-30 | Osaka City University | Clamping probe |
CN107746883B (zh) * | 2015-06-24 | 2021-03-23 | 湖北工业大学 | 基于肽核酸探针的Wnt信号通路中Pygo2基因R356P突变的检测试剂 |
CN107828872A (zh) * | 2015-06-24 | 2018-03-23 | 湖北工业大学 | 基于肽核酸探针的Wnt信号通路中Pygo2基因表达的检测试剂 |
CN105039522A (zh) * | 2015-06-24 | 2015-11-11 | 湖北工业大学 | 基于肽核酸探针的Wnt信号通路中FoxM1基因突变的检测试剂、PCR检测方法及应用 |
CN107893106A (zh) * | 2015-06-24 | 2018-04-10 | 湖北工业大学 | 基于肽核酸探针的Wnt信号通路中Bcl‑9基因T365I突变的检测试剂 |
KR102298421B1 (ko) * | 2015-11-19 | 2021-09-07 | 주식회사 팍스젠바이오 | 염기서열상의 다형성을 검출할 수 있는 방법 및 키트 |
CN107604053A (zh) * | 2017-08-16 | 2018-01-19 | 金绍莲 | 一种野生型扩增阻滞物在制备检测基因痕量突变试剂中的应用及其试剂盒和检测方法 |
US11634760B2 (en) | 2017-11-29 | 2023-04-25 | Panagene Inc. | Method for amplifying target nucleic acid and composition for amplifying target nucleic acid |
KR101919896B1 (ko) * | 2018-05-03 | 2018-11-19 | 주식회사 유디피아 | 단일 형광 채널 유전자증폭기기를 이용한 다중 핵산 검출 방법 |
KR102543156B1 (ko) * | 2020-11-24 | 2023-06-14 | 주식회사 파나진 | 높은 특이도의 표적핵산 증폭방법 및 이를 이용한 표적핵산 증폭용 조성물 |
CN112899357A (zh) * | 2021-01-05 | 2021-06-04 | 南京普济生物有限公司 | 一种运用数字pcr进行胎儿分数检测的方法及其试剂盒 |
KR102575618B1 (ko) * | 2021-03-22 | 2023-09-07 | 에이치엘비파나진 주식회사 | 가이드 프로브 및 클램핑 프로브를 이용한 표적핵산 증폭방법 및 이를 포함하는 표적핵산 증폭용 조성물 |
WO2024014734A1 (ko) * | 2022-07-12 | 2024-01-18 | (주)제노텍 | 특이도 및 민감도가 향상된 qpcr 방법 및 킷트 |
WO2024167181A1 (ko) * | 2023-02-08 | 2024-08-15 | 서울대학교산학협력단 | 돌연변이 핵산의 검출 방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714331A (en) * | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
WO1998003542A1 (en) | 1996-07-24 | 1998-01-29 | Buchardt, Dorte | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US7033763B2 (en) * | 2000-02-23 | 2006-04-25 | City Of Hope | Pyrophosphorolysis activated polymerization (PAP) |
KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
JP4216266B2 (ja) | 2005-04-15 | 2009-01-28 | 三菱化学メディエンス株式会社 | 高感度な既知変異遺伝子検出方法、およびegfr変異遺伝子検出方法 |
US20100009355A1 (en) * | 2006-03-14 | 2010-01-14 | Kolodney Michael S | Selective amplification of minority mutations using primer blocking high-affinity oligonucleotides |
WO2007147063A2 (en) * | 2006-06-16 | 2007-12-21 | Sequenom, Inc. | Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample |
US7803543B2 (en) | 2007-01-19 | 2010-09-28 | Chang Gung University | Methods and kits for the detection of nucleotide mutations using peptide nucleic acid as both PCR clamp and sensor probe |
EP2014774A1 (en) * | 2007-07-11 | 2009-01-14 | Pathofinder B.V. | Assay for the simulataneous detection of multiple nucleic acid sequences in a sample |
EP2288741B1 (en) * | 2008-05-14 | 2015-01-28 | University Health Network | Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy |
US8815515B1 (en) * | 2009-09-24 | 2014-08-26 | University Of Utah Research Foundation | Methods, compositions, and kits for rare allele detection |
KR101819937B1 (ko) * | 2009-10-19 | 2018-01-19 | 주식회사 파나진 | PNA 기반의 실시간 PCR 클램핑을 이용한 K-ras 돌연변이 검출 방법 및 키트 |
KR20110086963A (ko) | 2010-01-25 | 2011-08-02 | 주식회사 파나진 | Pna 기반의 실시간 pcr 클램핑을 이용한 인플루엔자 바이러스의 항바이러스제 내성 검출 방법 및 키트 |
EP2673381A4 (en) * | 2011-02-07 | 2014-10-15 | Univ Toronto | BIOSONDES AND METHOD FOR THEIR USE |
US20130005589A1 (en) * | 2011-06-29 | 2013-01-03 | Mitsubishi Chemical Medience Corporation | Highly sensitive method for detecting mutated gene |
SG2014010276A (en) | 2011-08-18 | 2014-03-28 | Nestec Sa | Compositions and methods for detecting allelic variants |
US9745633B2 (en) * | 2013-06-28 | 2017-08-29 | Diacarta Ltd | Detection of PNA clamping |
-
2014
- 2014-06-03 KR KR1020140067582A patent/KR101830700B1/ko active IP Right Grant
- 2014-10-14 EP EP14860780.7A patent/EP2912176B1/en active Active
- 2014-10-14 CN CN201480061608.3A patent/CN105765068A/zh active Pending
- 2014-10-14 JP JP2016530173A patent/JP6228674B2/ja active Active
- 2014-10-14 US US14/648,909 patent/US10648019B2/en active Active
- 2014-10-14 WO PCT/KR2014/009611 patent/WO2015068957A1/en active Application Filing
-
2017
- 2017-10-13 JP JP2017199346A patent/JP2018033463A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190001742A (ko) * | 2017-06-28 | 2019-01-07 | 주식회사 파나진 | 양자점을 분산광원으로 하는 표적 핵산 검출 방법 |
KR102083396B1 (ko) | 2017-06-28 | 2020-03-02 | 주식회사 파나진 | 양자점을 분산광원으로 하는 표적 핵산 검출 방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2018033463A (ja) | 2018-03-08 |
US10648019B2 (en) | 2020-05-12 |
JP2017501683A (ja) | 2017-01-19 |
EP2912176A4 (en) | 2016-07-27 |
WO2015068957A1 (en) | 2015-05-14 |
EP2912176B1 (en) | 2020-07-29 |
KR101830700B1 (ko) | 2018-02-21 |
EP2912176A1 (en) | 2015-09-02 |
US20170198340A1 (en) | 2017-07-13 |
KR20150054633A (ko) | 2015-05-20 |
CN105765068A (zh) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6228674B2 (ja) | クランピングプローブ及び検出プローブを用いた多重標的核酸の検出方法 | |
JP6464316B2 (ja) | 水産生物伝染病原因ウイルスの判別及び検出用遺伝子マーカー、及びこれを利用した当該ウイルスを判別及び検出する方法 | |
JP5531367B2 (ja) | 標的配列の濃縮 | |
CN110621784B (zh) | 使用双功能pna探针诊断微卫星不稳定性的方法和诊断微卫星不稳定性的试剂盒 | |
KR102371222B1 (ko) | 표적핵산 증폭방법 및 표적핵산 증폭용 조성물 | |
JP2016535987A (ja) | 核酸配列の合成及び濃縮 | |
US20190106735A1 (en) | Method for analyzing cancer gene using multiple amplification nested signal amplification and kit | |
KR20150136558A (ko) | Pna 프로브 및 형광융해곡선분석을 이용한 혈액형 판별방법 | |
WO2011104695A2 (en) | Detection of kras mutation in exon 2 by allele specific real time quantitative pcr (as-qpcr) | |
CN111615561B (zh) | 单核苷酸多态性检测用寡核苷酸探针和顺式-反式判别方法 | |
KR102543156B1 (ko) | 높은 특이도의 표적핵산 증폭방법 및 이를 이용한 표적핵산 증폭용 조성물 | |
KR102575618B1 (ko) | 가이드 프로브 및 클램핑 프로브를 이용한 표적핵산 증폭방법 및 이를 포함하는 표적핵산 증폭용 조성물 | |
KR101737318B1 (ko) | 노랑머리병 바이러스 검출용 유전자 마커, 및 이를 이용한 바이러스의 검출 방법 | |
US20240318240A1 (en) | Target nucleic acid amplification method using guide probe and clamping probe and composition for amplifying target nucleic acid comprising same | |
KR20160036906A (ko) | 프로브 혼합체의 반응성을 높일 수 있는 프라이머 및 그의 용도 | |
WO2016103727A1 (ja) | 特異的核酸配列の増幅促進方法 | |
KR101737313B1 (ko) | 전염성 근괴사증 바이러스 검출용 유전자 마커, 및 이를 이용한 바이러스의 검출 방법 | |
Botezatu et al. | Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes | |
KR20160134094A (ko) | 펩티드핵산을 이용한 항체 의존성 세포 독성에 관여하는 항체 Fc 감마 리셉터의 유전자형 판별방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170913 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171013 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6228674 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |